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Abstract
Purpose α-Blockers are commonly used for the treatment of male lower urinary tract symptoms (LUTS). The Dutch GP 
guideline on male LUTS contains an advice to discontinue treatment after 3–6 months of successful treatment. The guideline 
for urologists does not support this advice. It is unclear if these differences lead to other patterns of (dis)continuation of 
α-blockers. We aim to study continuation rates of α-blockers, prescribed by a urologist or a general practitioner (GP), and 
to predict discontinuation after 1 year.
Methods We conducted a retrospective inception cohort study on prescription patterns of α-blockers among Dutch men 
between 2006 and 2014, using the IADB.nl pharmacy prescription database from the University of Groningen. We selected 
men aged 30 years or older with a first α-blocker prescription between 2006 and 2013, and analysed continuation of 
prescriptions.
Results The database included 12,191 individual patients with at least one α-blocker prescriptions from a urologist (44.5%) 
or a GP (55.5%). The median treatment period for patients who started in the GPs office was 210 days, compared to 150 days 
for patients with a prescription from a urologist. Of all patients, 60.3% (GP prescriptions) and 66.1% (urologists’ prescrip-
tions) had discontinued treatment (Chi-square p < 0.001). Discontinuation rates were age dependent with higher rates in the 
youngest age groups.
Conclusion In this study, the discontinuation rate 1 year after the initiation of treatment was high. Although Dutch GP’s 
and urologist’s guidelines differ with respect to a discontinuation advice, we could not find clinically relevant difference in 
(temporary) discontinuation rates.
Keywords α-Blockers · Prescription patterns · Urologists · General practitioners · Lower urinary tract symptoms
Introduction
The pharmacological treatment in male LUTS generally 
starts with α-blocker therapy [1–3]. The Dutch general prac-
titioner (GP) guideline “male LUTS” contains an advice to 
discontinue α-blocker therapy after 3–6 months of use [3]. 
This advice is based on the overall variable LUTS severity 
over time [4], but has no further evidence base. The guide-
line of Dutch urologists does not support this recommenda-
tion; neither does the guideline of the European Association 
of Urologists (EAU) [2]. In the latter, discontinuation of 
α-blockers is only suggested for men who receive combina-
tion treatment with a 5-α-reductase inhibitor [2].
Whether this difference in guideline advises leads to 
other prescription patterns between GPs and urologists has 
not been studied. We evaluated prescription patterns in the 
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first year of α-blocker treatment in men initiated by Dutch 
GPs and urologists. We examined discontinuation rates as 
well as predictors for discontinuation in incident patients 
on α-blockers.
Materials and methods
Study design, data source and study population
We have conducted a retrospective inception cohort study. 
In this study, we analysed prescription patterns of α-blockers 
between 2006 and 2014 in Dutch men. The University of 
Groningen IADB.nl pharmacy prescription database (IADB.
nl) provided all data. The IADB database contains informa-
tion on all prescriptions dispensed by 60 Dutch community 
pharmacies [5]. This includes over 1.2 million patients with 
more than 100 million unique prescriptions. The IADB data-
base includes no information on the indication for treatment. 
Nor does it contain additional patient information, other than 
age and sex. Population distribution and drug use were to a 
large extent comparable to the Dutch general population [5].
We selected men aged 30 years or older who had a first 
α-blocker mono-therapy prescription between 2006 and 
2013, based on the anatomic therapeutic chemical clas-
sification (ATC)-codes G04CA01, G04CA02, G04CA03 
and G04CA04. These codes do not include α-blockers used 
for the treatment of hypertension. We did not select new 
prescriptions of combination therapy (ATC codes G04CB, 
G04CA52, and G04CA53); as such, therapy is not recom-
mended in the Dutch GP guideline [3] and our main aim 
was to compare prescriptions from GPs with prescriptions 
from urologists.
A prescription was considered a first prescription if there 
were no identical prescriptions present in the two preceding 
years. We categorised the first prescriber as either GP or 
specialist/urologist. For every included patient who could be 
followed for 52 weeks, we retrieved all dispensed α-blocker 
prescriptions and other urologic prescriptions from the data-
base. Within the IADB database, patient status is listed as 
active or inactive, due to moving out of the area or dying. In 
the Netherlands, the vast majority of patients obtained their 
medications from one pharmacy, mostly situated nearby the 
patients’ home.
We calculated the total duration of α-blocker use in 
days, by dividing the number of doses dispensed by the 
pharmacy by the number of doses per day and evaluated 
drug usage at 2, 6, 13, 26, 39 and 52 weeks after the date 
of first prescription. We classified patients classified as 
“discontinued” if the total duration (in days) was less than 
these periods. If total duration exceeded these periods, we 
classified patients as “current users”. We did this for each 
point in time. For “current users”, we examined if at any 
time interval, the patient had had a period of discontinua-
tion. We defined a period of discontinuation if 15 tablets or 
more were missing in the preceding period. So this reflects 
a gap in refills. With this information, we classified current 
users as “temporary discontinuation” or “no temporary 
discontinuation”.
Statistical analysis
We present descriptive statistics with mean ± standard 
deviation for continuous data or percentage for categorical 
data. We compared the differences in (temporary) discon-
tinuations rates between GPs and urologists, age groups 
(30–49, 50–59, 60–69, 70–79 and 80–100 years), and 
year of first prescription, using Chi-square tests. Next, we 
entered these possible predictors in a multivariable logistic 
regression analysis to predict current use after 1 year. We 
calculated the odds-ratio and corresponding 95% confi-
dence interval (95% CI). We applied the Nagelkerke R2 to 
assess the percentage of explained variance and the Hos-
mer–Lemeshow test to determine the goodness-of-fit of 
our model. We considered a p value < 0.05 as statistically 
significant. All analyses were performed using SPSS Ver-
sion 25.
Results
We identified 12,191 individual patients with one or more 
α-blocker prescriptions. In 5419 cases, urologists provided 
the first prescription. In the other 6772 cases (55.5%), GPs 
were the prescribers. Baseline characteristics are presented 
in Table 1.
The median treatment period for patients who started in 
the GPs office and in hospital was 210 days and 150 days, 
respectively. Figure 1 shows the number of current users at 
2, 6, 13, 26 and 52 weeks for the complete sample. These 
numbers showed no relevant differences between the two 
prescriber groups (see supplementary file). Of all patients, 
60.3% and 66.1% of, respectively, GP’s and urologists’ 
patients had discontinued treatment (Chi-square p < 0.001) 
within 1 year after initiating α-blocker treatment.
Discontinuation rates were age dependent with higher 
rates in the youngest age groups (see Table 2). At each point 
in time, we found the differences to be statistically signifi-
cant (all Chi-square, p < 0.05).
Age, prescriber and year of first prescription were inde-
pendent predictors of current use after 1 year of treatment in 
the multivariable logistic regression analysis (see Table 3). 
The percentage of explained variance for this model was 
6.1% (Nagelkerke R2).
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Table 1  Baseline characteristics 




N (%) 12,191 6772 (55.5) 5419 (44.5)
Age, mean ± SD 65.3 ± 12.2 65.8 ± 11.8 64.6 ± 12.7
Age group, N (%)
 30–49 1281 (10.5) 554 (8.2) 727 (13.4)
 50–59 2483 (20.4) 1436 (21.2) 1047 (19.3)
 60–69 3836 (31.5) 2219 (32.8) 1617 (42.2)
 70–79 3004 (24.6) 1645 (24.3) 1359 (25.1)
 80–100 1587 (13.0) 918 (13.6) 669 (12.3)
α-Blocker, N (%)
 Alfuzosin 3175 (26.0) 2227 (32.9) 948 (17.5)
 Tamsulosin 8981 (73.7) 4535 (67.0) 4445 (82.0)
 Terazosin 8 (0.1) 5 (0.1) 3 (0.1)
 Silodosin 27 (0.2) 5 (0.1) 22 (0.4)
Combination therapy, n (%) 935 (7.7) 241 (3.6) 694 (12.8)
Median duration of therapy, days (IQR) 180 (45–857) 210 (45–735) 150 (45–735)
Fig. 1  Numbers and percent-
ages of patients who discontin-
ued and continued α-blocker 
treatment (with or without gap)
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Discussion
This pharmacy-based study shows that the majority of men 
who start an α-blocker discontinue its use within 1 year. 
In this respect, no clear differences are shown between 
patients with a first prescription from a GP or from a urol-
ogist. Only a minority of men who still use the α-blocker 
after 1 year have had a period of discontinuation.
The main limitation of this database study is that no 
clinical information is available from the patients and 
indications for prescriptions are not recorded which might 
have led to misclassification. Information was limited to 
patient age, date of prescription, and prescriber. In the 
Netherlands, α-blockers are also prescribed for stone 
expulsive therapy and in case of acute urinary retention to 
support trial without catheter [3]. The incidence of both 
problems is generally low, although especially urolithiasis 
might explain the high discontinuation rate after 6 weeks 
(50.9%) in the youngest age group.
Next, it is unclear if patients discontinued α-blocker 
use themselves, for example due to side effects or a lack of 
effectiveness, or if physicians actively gave the advice to 
stop its use. We expect that short-term use may especially 
be associated with lack of effect on symptom severity, 
side effects, or with other indications, such as urolithi-
asis. Previously, Koh et al. showed that resolved symptoms 
(31.1%), no symptom improvement (23.7%) and adverse 
events (20.0%) were the main reasons for discontinua-
tion [6]. Another limitation may be the low percentage of 
explained variance of the regression model. This shows 
that other variables contribute to the treatment patterns, 
which were not taken into account in the analyses. In the 
American cohort study, the percentage of explained vari-
ance was not reported [7].
The main strength of this study is the large number of 
patients from whom information is available. This database 
is representative for the Netherlands [5]. Most patients in 
the Netherlands collect their prescriptions from a single 
pharmacist. α-Blockers are by no means available without 
a prescription. In the Netherlands, the pharmacists dispense 
each first prescription only for 2 weeks with an automated 
extension of this period based on the prescription. If patients 
did not understand that usage was meant for a longer period, 
this could explain part of the discontinuation after 2 weeks.
Although α-blockers are generally considered to be effec-
tive for the treatment of male LUTS, the discontinuation 
rate was high in this study, as well as in three other studies 
[6–8]. In the first study, it was is unclear who was the first 
prescriber [8], whereas in the second study a combination 
of α-blocker and 5-α-reductase inhibitor prescriptions from 
a urologist was examined [6]. More recently, Rensing et al. 
showed in a large American cohort that discontinuation most 
frequently occurred in the first year after initiating treatment 
and resulted in a cumulative incidence of 53.1 (urologists) 
and 55.4% (PCPs) after 3 years [7]. For all prescriptions 
(α-blockers, 5ARI and anticholinergics), authors found a 
statistically significant difference in discontinuation rates 
between urologists and PCPs: hazard ratio 1.19 (CI 95% 
1.09−1.29) [7]. We feel that this small difference is not clini-
cally relevant.
Table 2  Cumulative percentage 
of complete discontinuation 
according to age and time
The differences between age categories were statistically significant at each point in time (Chi-square, 
p < 0.05)
Time (weeks) 30–49 years 50–59 years 60–69 years 70–79 years > 80 years
0–2 27.8% 15.1% 10.3% 9.3% 11.5%
2–6 50.9% 29.0% 22.6% 21.8% 22.8%
6–13 65.2% 41.1% 32.7% 31.7% 31.9%
13–26 78.7% 56.1% 46.1% 42.4% 45.3%
26–39 83.5% 62.5% 53.7% 49.6% 52.4%
39–52 86.7% 68.3% 58.7% 55.9% 58.0%
Table 3  Predictors of current use 1 year after initiation of α-blocker 
therapy
Hosmer–Lemeshow = 0.24, Nagelkerke R2 = 0.061
Factors Odds ratio (95% CI)
Prescriber








Year of first prescription
 2006 and 2007 1.00 (referent)
 2008 and 2009 0.97 (0.87–1.08)
 2010 and 2011 0.93 (0.04–1.03)
 2012 and 2013 0.78 (0.70–0.86)
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A possible explanation of the high discontinuation in 
these and our studies may be that many men do not expe-
rience a clinically relevant effect, because LUTS have a 
multifactorial origin whilst α-blockers only influence one 
specific aspect [9, 10]. Although this is recognised in current 
guidelines, especially due to the low number of side effects 
and low costs of α-blockers, these drugs are advised for all 
men with uncomplicated LUTS who opt for active treatment.
Shortridge et al. showed much lower discontinuation 
rates, in a study using electronic medical records of 1807 
patients with LUTS/BPH: 11.6% after 1 year [11]. This large 
difference may be explained by the inclusion criteria applied. 
To meet the inclusion criteria in that study, participants were 
required to have two or more prescriptions. So the high dis-
continuation rates in the first weeks of use, as shown in our 
study population, are excluded in that study. Finally, in the 
largest database on this topic, Cindolo et al. showed that the 
1-year adherence in Italian men exposed to at least 6 months 
of mono-therapy or combination therapy [12]. The authors 
found that only 29% of these men adhered to therapy. We 
cannot explain the very large difference with our results. In 
men who used α-blockers for at least 6 months, 75% still 
used their medication after 1 year.
α-Blockers are the mainstay of pharmacological treatment 
of male LUTS. This is a “one size fits all” or “trial and error” 
strategy, focussing on one aspect of the male lower urinary 
tract. Defining subgroups of men with a higher chance of 
successful α-blocker treatment would serve patients and 
their physicians, and reduce the high discontinuation rates, 
simply by not initiating this treatment if the chance of suc-
cess is low. As it is unlikely that new randomised controlled 
trials will be conducted for this drug group, observational 
studies based on real life practice may provide support for a 
more personalised approach.
Conclusion
We found a high discontinuation rate after 1 year of treat-
ment, with about two-thirds of new patients discontinued 
treatment within 1 year. A period of discontinuation was 
seen in only 30% of patients who still used α-blockers 1 year 
after treatment initiation. Despite the differences between 
Dutch GP’s and urologist’s guidelines with respect to a 
discontinuation advice, the differences in (temporary) dis-
continuation rates described in this study are not clinically 
relevant.
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